United States Veterinary Intravenous Solution Market Size & Outlook, 2026-2034
United States Veterinary Intravenous Solution Market Insights
- As per Reed Intelligence insights, the United States Veterinary Intravenous Solution Market stood at USD 341.7 Million in 2025 and is anticipated to grow to USD 670.12 Million by 2034.
- The United States market is expected to advance at a CAGR of 7.94% from 2026 through 2034.
- In 2025, Isotonic Crystalloid Solutions accounted for the highest share of the Product Type market size.
- During the forecast period, Blood and Plasma Products is set to register the highest growth, making it the most lucrative Product Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2025, United States held 24.06% of the global Veterinary Intravenous Solution Market size.
- By 2034, United States is anticipated to capture the largest share of the global Veterinary Intravenous Solution Market.
- In North America, United States is expected to lead the regional Veterinary Intravenous Solution Market size by 2034.
- Canada will remain the fastest-growing market in North America, reaching USD 178.9 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 341.7 Million |
| Market Size In 2034 | USD 670.12 Million |
| Largest segment | Isotonic Crystalloid Solutions |
| Units | Revenue in USD Million |
| CAGR | 7.94% (2026-2034) |
| Segmnetation Covered | |
| Product Type |
|
| Animal Type |
|
| End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Veterinary Intravenous Solution Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Isotonic Crystalloid Solutions | XX.x | XX.x | XX.x | 146.9 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hypertonic Solutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Colloid Solutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Parenteral Nutrition Solutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Blood and Plasma Products | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Veterinary Intravenous Solution Market Animal Type 2026-2034 (USD Million)
| Animal Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Companion Animals | XX.x | XX.x | XX.x | 166.79 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Livestock Animals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Equine Animals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Exotic Animals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Veterinary Intravenous Solution Market End Use 2026-2034 (USD Million)
| End Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veterinary Hospitals | XX.x | XX.x | XX.x | 148.47 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Veterinary Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Homecare and Mobile Veterinary Services | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research and Academic Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.